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Introduction
Many surveillance drugs consumption programs, [1, 2, 
3, 4] and strategies, [5, 6, 7] are used to achieve a prudent 
use of antibiotics in medical care institutions and quality of 
the anti-infective treatment of hospitalized patients. Never-
theless, a large proportion of antibiotic prescriptions is inap-
propriate, and constitutes up to 50% of prescriptions only in 
the United States and Canada. That’s why, it is important to 
reduce the misuse and overuse of these important resources 
[8]. The primary aim of the study was to evaluate the insti-
tutional representative data on utilization of main antibacte-
rial groups like tetracyclines, amphenicols, beta-lactam an-
tibacterials and penicillins, other beta-lactam antibacterials, 
macrolides and lincosamides, aminoglycoside antibacterials, 
quinolone antibacterials, other antibacterials and antymi-
cotics in accordance with the World Health Organization 
(WHO) requirements, which are directed to determine the 
value of Defined Daily Doses per 1000 Occupied-Bed Days 
(DDD/1000) [9] in the dynamics per total institution and 
most important departments, and to be compared with the 
same published data in international scientific journals.
Material and methods
For this study we used the data of a six-year (2010-2014) 
period consumption of antibacterials in Emergency Medi-
cine Institute (EMI) and its main subdivisions: Intensive 
care departments (ICD), that include (Reanimation, Inten-
sive Therapy and intensive “STROKE” departments) as well 
as SSOTD (Septic surgical and Septic Orhtotraumotology 
departments) which show the dynamics of consumption 
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Abstract
Background: Antibiotics have had a profound impact on humanity’s health, by improving our ability to prevent, cure and reduce the transmission of 
many infectious diseases. It is widely known, that the unnecessary or inappropriate use of antibiotics, occurs up to 50% of prescriptions only in the United 
States and Canada. Fortunately all negative impact on the human health can be roughly imagined.
Material and methods: For this study we used the data of a six-year (2009-2014) period in the Emergency Medicine Institute and their main subdivisions 
which show the consumption dynamics of antibacterials use in natural indexes.
Results: The total annual medium consumption of antimicrobials was registered as the following: ICD 1796.98 DDD/1000, SSOTD 566.12 DDD/1000 
and EMI 584.05DDD/1000, with the parenteral to enteral forms share of respectively 94.67% to 5.33%, 85.62% to 14.38% and 83.52% to 16.48%. Five from 
nine main groups: beta-lactam antibacterials, penicilins, other beta-lactam, aminoglycoside, other antibacterials and quinolone antibacterials registered 
around 90% of all antibiotics consumption. Comparatively to Australian hospitals and hospitals other worldwide countries in EMI consumption per 
DDD/1000 was lower: by 3.39 and 2.22 times for tetracyclines, by 5.1 and 4.63 for beta-lactam and penicilins, as well as by 2.55 and 1.63 for macrolides 
and lincosamides.
Conclusions: The obtained data about the dynamics of antibacterials consumption in EMI and their main departments, in comparison with hospitals 
from other worldwide countries, represents important arguments and reserves for improving quality treatment, planning, rational prescription and 
utilization of antibiotics in hospitals.
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of main groups of antiinfectives for systemic use drugs as 
classified by Anatomical Therapeutic Chemical (ATC), clas-
sification system of the World Health Organization (WHO) 
indicated in grams and value indexes. Statistical, analytical, 
mathematical, comparative, logical and descriptive were 
used as the methods of study.
Results and discussion
For determining the number of DDD/1000 we used data 
about total annual consumption of antimicrobials and the 
statistics data concerning the number of treated patients 
(only patients with health insurance and other free treated 
by the state categories of citizens) [10].
Despite the fact that the use of tetracycline in hospitals 
holds some of the last positions in consumption among oth-
er antibiotics subgroups, antimicrobial therapy treatment 
of severe acute respiratory diseases (SARS) includes tetra-
cycline (91.0%) and its combination with other antibiotics: 
tetracyclines and aminoglycosides in 18.8% of the patients, 
tetracyclines and quinolones in 11.5%, also 63.5% received 
a combination of tetracyclines, aminoglycosides and quino-
lones, [11, 12]. In some hospitals from other countries me-
dium consumption for tetracycline recorded the following 
0.5-27-70.00 DDD/1000 [13]. Tetracyclines consumption in 
EMI is characterised by the use of doxycyclinum with 0.1g 
defined daily doses.  In the last 3 years of the evaluated pe-
riod a total considerable increase of consumption was re-
corded: from 21.07 to 143.22 DDD/1000 or by 6.80 times in 
all departments, from 5.9 to 106.6 in intensive Therapeutical 
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During the last decades in many countries of the world, 
Amphenicol consumption was limited from 0.62 to 0.01% 
or totally absent [14, 15]. Notwithstanding, due to the in-
crease of antimicrobial resistance to all antibiotics, in some 
countries has been renewed the interest to old drugs that 
have fallen into disuse. One of such examples is Israel, where 
Chloramphenicolum with susceptibility is routinely assessed 
in 44.4% – 83.3% of hospitals mostly for the treatment of as-
piration pneumonia, [16]. In EMI the medium institutional 
amphenicols consumption constitued less than 1 DDD/1000 
and recorded an increase during the years 2009-2014 from 
0.5 to 0.8 DDD/1000 or by 40%, as well all in the evaluated 
departments of 5.37 to 9.45 DDD/1000 or by 175.98%.
The beta-lactam antibiotics remain the most heavily used 
antibacterials in clinical medicine. The annual consumption 
in US is estimated to be in the range of 10–30 million tons, 
which continues to increase, [17, 18]. From all antibiotics in 
hospitals, the use of beta-lactam recorded in mean 30-50%, 
[19, 20]. In EMI consumption of this group is characterised 
by use of parenteral (P) and enteral (E) forms of Ampicil-
linum with DDD 2.0 P and 2.0E, Amoxicillinum DDD 1.0 P 
and 1.0 E, Amoxicillinum+ Acidum clavulanicum ICD with 
DDD 3.0 P and 1.0 E, Ticarcillinum DDD with 15.0 P. Total 
beta-lactam antibacterials and penicillins consumption in 
main departments of EMI in DDD/1000 during 2009-2014 
is shown in figure 1.
Fig. 1. Total beta-lactam antibacterials and penicillin 
consumption in DDD/1000 during 2009–2014.
From figure 1, it could be observed a total decrease of 
consumption of the group of antibiotics from 516.88 in 2009 
to 356.82 DDD/1000 in 2014 or by 25.40%. From the an-
nual medium consumption of 562.51 DDD/1000 could 
be placed as follows: the first – Reanimation department 
with 178.08 DDD/1000 or 31.66%, the second – Intensive 
Therapy department with 131.82 DDD/1000 or 23.43%, the 
third – “STROKE” intensive care department with 105.25 
DDD/1000 or 18.71%, the fourth – septic Orhtotraumotol-
ogy department with 84.37 DDD/1000 or 15.00% and septic 
Surgical department with 62.99 DDD/1000 or 11.20% on the 
fifth position.
All around the world in hospitals the consumption of 
other beta-lactam antibiotics recorded in mean 15-20% of 
all antibiotics, [21, 22, 23], whereas in EMI 50-60%. That 
situation determined a higher attention for this group of 
anti-infectives for systemic use. Total other beta-lactam an-
tibacterials consumption in DDD/1000 during 2009-2014 is 
shown in figure 2.
Fig. 2. Total other beta-lactam antibacterials consumption in 
DDD/1000 during 2009–2014.
From figure 2, it could be observed a total increase of 
other beta-lactam antibacterials consumption for all de-
partments from 1893.69 DDD/1000 in 2009 to 2373.49 
DDD/1000 or by 25.30%. According to the all departments 
annual medium consumption of 2701.58 DDD/1000 is 
placed as  following: the first – Reanimation department with 
970.38 DDD/1000 or 35.92% and a decrease from 1416.54 
to 886.7 DDD/1000 or by 37.34%, the second – Intensive 
Therapy department with 794.95 DDD/1000 or 29.43% and 
a decrease from 974.67 in 2010 to 597.7 or by 38.68%, the 
third – Intensive Neurological “STROKE” department with 
467.76 DDD/1000 or 17.31% and a decrease from 509.6 in 
2013 to 425.95 or by 16.42%, the fourth – septic Surgical de-
partment with  237.92 DDD/1000 or 8.81% and a decrease 
from 310.05 to 187 DDD/1000 and septic Orhtotraumotol-
ogy department with 230.57 DDD/1000 or 8.53% and an in-
crease from 167.1 to 276.14 DDD/1000 or by 65.25% on the 
fifth position.
Consumption of macrolides and lincosamides anti-
bacterials in EMI is characterised by use of parenteral (P) 
and enteral (E) forms as folowing: Erytromycin DDD 1.0 
E, Midecamycinum DDD 1.0 E, Clarithromycinum DDD 
0.5 EP, Azithromycinum DDD E0.3, P.5, Lincomycinum 
DDD 1.8 P.
A total decrease of macrolides and lincosamides con-
sumption for all departments constituted from 108.77 in 
2009 to 26.56 DDD/1000 in 2014 or by 75.58% and varied 
considerably in every subdivision during the evaluated pe-
riod.
In hospitals from other countries, medium consump-
tion for aminoglycosides recorded the following: 40.00 to 
50.00DDD/1000 or not more than 5% of all amounts of an-
tibiotics. At the same time consumption in ICD for critically 
affected patients is higher and varied between 38-66%, [22, 
23]. In EMI, aminoglycoside antibacterials are presented by 
use of parenteral forms of the following antibiotics: Strepto-
mycinum 1.0 P, Gentamycinum 0.2 P, Kanamycinum 1.0 P 
and Amikacinum 1.0 P defined daily doses.
In figure 3 the total consumption of aminoglicosides in 
DDD/1000 during 2010-2014 is shown.
Figure 5 demonstrates a total decrease in consumption 
of aminoglycosides for all departments during 2009 and 
2010 from 780.30 to 677.89 DDD/1000 and a steep increase 
to 982.25 DDD/1000 in 2013, followed by a spontaneous 
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decrease to 677.27 DDD/1000 in 2014 or by 31.05%. From 
the annual medium consumption of 832.24 DDD/1000, in 
all departments, the standings are the following: the first – 
Reanimation department with 326.37 DDD/1000 or 39.21%, 
the second – septic Orhtotraumotology department with 
196.80 DDD/1000 or 23.64%, the third – intensive Neuro-
logical “STROKE” department with 165.38 DDD/1000 or 
19.17%,  the fourth – intensive Therapy department with 
76.31 DDD/1000 or 9.17%, and septic Surgical department 
with  67.47 DDD/1000 or 8.11% on the fifth position.
Quinolone, is a broad-spectrum antibiotic, which plays 
an important role in the treatment of severe bacterial infec-
tions, especially hospital-acquired infections and has one 
more priority recommended as first-line therapy [24]. Con-
sumption in EMI is characterised by the use of parenteral 
(P) and enteral (E) forms as the following: first-generation: 
Acidum pipemidicum ICD DDD 0.8 E,P, second-generation: 
Ofloxacinum DDD 0.4 E,  Ciprofloxacinum DDD 1.0 E, 0.5 
P, fourth-generation: Gatifloxacinum DDD 0.4 E,P and Mo-
floxacin with DDD 0.4 E,P. During the period 2009 to 2013 
a total steep decrease from 583.42 to 185.63 DDD/1000 in 
consumption of quinolone antibacterials, followed by a 
significant increase to 469.65 DDD/1000 in 2014. In com-
parison with the annual medium consumption of 468.16 
DDD/1000 the main three positions could be placed as the 
following: the first place – Reanimation department with 
213.16 DDD/1000 or 45.62%, the second – intensive Neu-
rological “STROKE” department with 84.04 DDD/1000 or 
17.95% and the third – Intensive Therapy department with 
80.26 DDD/1000 or 17.14%.
Consumption of other antimicrobials in EMI is charac-
terised by the use of parenteral (P) and enteral (E) forms as 
the following: glycopeptide antibacterials: Vancomycinum 
DDD 2.0 P, imidazole derivatives: Metronidazolum DDD 1.5 
P, nitrofuran derivatives: Furazidinum DDD 0.2 E, Nitrofu-
rantoinum DDD 0.2 E and other antibacterials: Dioxydinum 
DDD 0.7 P and Nitroxolinum DDD 1.0 E.
Total other antibacterials consumption in DDD/1000 
during 2009-2014 is shown in figure 4.
From figure 4, it can be stated a considerable decrease of 
other antibacterials consumption during 2009 and 2012 from 
607.50 to 312.92 DDD/1000 of the total consumption or by 
48.49%, followed by a steep increase to 551.08 DDD/1000 
in 2014 or by 76.11%. According to the all departments an-
nual medium consumption of 477.3 DDD/1000, could be 
placed as follows: the first – intensive Therapy department 
with 244.42 DDD/1000 or 51.22%, the second – Reanima-
tion department with 167.7 DDD/1000 or 35.14%, the third 
– intensive Neurological «STROKE» department with  88.31 
DDD/1000 or 18.5%, the fourth – septic Surgical depart-
ment with 47,06 DDD/1000 or 9.86% and septic Orhtotrau-
motology department with 29.35 DDD/1000 or 6.15% on 
the  fifth position.
Fig. 4. Total other antibacterials consumption in DDD/1000 
during 2009–2014.
Despite the fact that the use of antibiotics in many parts 
of the world has been described in details, the data concern-
ing the use of antimycotics for systemic use such as imidazole 
derivatives and triazole derivatives are scarce, [25, 26]. Con-
sumption in EMI is characterised by use of parenteral (P) 
and enteral (E) forms as the following: imidazole derivatives: 
Ketoconazolum DDD 0.2 E and Triazole derivatives: Flucon-
azolum with DDD 0.2 E, P. A total decrease in consumption 
of antimycotics for systemic use for all departments during 
2009 and 2010 from 190.65 to 131.48 DDD/1000 and a steep 
increase to 231.22 DDD/1000 in 2013, followed by a sponta-
neous decrease to 108.91 DDD/1000 in 2014 or by 52.88%. 
More than 100 DDD/1000 from the annual medium con-
sumption of 198.54 DDD/1000 in all departments recorded 
only Reanimation department with 105.25 DDD/1000 or 
53.01%.
Evaluation of consumption of main groups of antimicro-
bials for systemic use  shows a medium annual (for 6 years) 
period for: Reanimation department of 1981 DDD/1000, 
intensive Therapy department of 1192 DDD/1000,  inten-
sive Neurological “STROKE” department of 965 DDD/1000, 
septic Surgical department of 965 DDD/1000 and for sep-
tic Orhtotraumotology department of of 657 DDD/1000. A 
total decrease since 2009 until 2014 of antimicrobials con-
sumption for ICD from 3273.79 to 1281.71 DDD/1000 or by 
60.85%, for SSOTD from 631.14 to 515.54 DDD/1000 or by 
18.32% and for EMI from 662.4 to 464.1 or by 29.94% during 
the evaluated period was recorded.
To determine the correlation between parenteral and 
enteral forms of evaluated antibiotics, was counted total by 
forms DDD/1000 separately for ICD and SSOTD and divid-
ed by the number of those departments (3 and respectively 
2).  The results are shown in table 1.
Data from table 1 shows the total annual medium 
consumption during 6 years, recorded for ICD 1801.00 
DDD/1000, SSOTD 581.72 DDD/1000 and EMU 584.05 
DDD/1000. Parenteral and enteral forms of use from total 
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DDD/1000 consumption in ICD departamentals repre-
sent 94.46% to 5.54%, in SSOTD departments respectively 
84.94% to 15.06%, as well as for EMI 83.52% to 16.48%. Five 
from nine main groups: beta-lactam antibacterials and peni-
cilins, other beta-lactam, aminoglycozide, other antibacteri-
als and quinolone antibacterials of the total medium con-
sumption represents 1673.05 or 92.90% in ICD departments, 
524.78 or 90.21% in SSOTD departments and respectively 
515.32 or 88.23% in EMI. In table 2, comparative medium 
data of antimicrobials consumption per DDD/1000 in EMI 
and some international hospitals and perceptual change dur-
ing 2009 to 2014 years are shown.
The results from table 2 show that during the evaluated 
period tetacycline consumption recorded an increament by 
more than 250% in EMI and Australian hospitals, when in 
the second case, it was recorded by 3.39 (51.75:15.25) as well 
as by 2.22 (33.80:15.25) times higher in other international 
hospitals, [27, 28, 29, 30]. The similar report by 5.1 and 4.63 
times more could be mentioned for beta-lactam antibacteri-
als, penicilins, as well as for macrolides and lincosamides by 
2.55 and 1.63 times more. A decrease in consumption was 
recorded for aminoglycozide antibacterial, quinolone anti-
bacterials and other antibacterials.The percentage changes 
in consumption of antimicrobial for systemic use for other 
international hospitals can’t be counted, because evaluated 
data were for the period of 1 or not more than 2 years.
Conclusions
1. Five from nine main groups: the beta-lactam antibacteri-
als, penicilins, the other beta-lactam, the aminoglycoside, the 
other antibacterials and the quinolone antibacterials registered 
around 90% of all consumption. Comparatively to Australian 
hospitals and other hospitals in foreign countries in EMI con-
sumption per DDD/1000 was less by: 3.39 and 2.22 times for 
tetacyclines, 5.1 and 4.63 for beta-lactam and penicilins, and 
by 2.55 and 1.63 for macrolides and lincosamides.
2. Medium annual consumption in the evaluated period 
recorded the following results: in Reanimation department 
1981 DDD/1000, intensive Therapy department 1192 
DDD/1000, intensive Neurological ”STROKE” department 
965 DDD/1000, septic Surgical department 965 DDD/1000 
and in Septic Orhtotraumotology department 657 DDD/1000.
3. Total annual medium consumption of antimicrobi-
als recorded for ICD 1801.00 DDD/1000, SSOTD 581.72 
DDD/1000 and for EMU 584.05 DDD/1000, with the paren-
teral and enteral forms share respectively 94.46% to 5.54%, 
84.94% to 15.06% and 83.52% to 16.48%.
4. A total decrease during the evaluated period of anti-
microbials consumption for ICD from 3273.79 to 1281.71 
DDD/1000 or by 60.85%, for SSOTD from 631.14 to 515.54 
DDD/1000 or by 18.32% and for EMI from 662.4 to 464.1 or 
by 29.94% was recorded.
5.  Obtained data about consumption dynamics of antibac-
terials in EMI and its main departments in comparison with 
Table 1
Correlation between parenteral and enteral forms of consumption  
of maim group of antibacterials in DDD/1000 in ICD, SSOT departments and EMI
Departments of and EMI ICDD SSOTD EMI
Groups of antibacterials/ 
forms of use P E T P E T  P E T 
Tetracyclines 0 9.6 9.6 0 11 11 0 15.25 15.25
Amphenicols 3.52 0.27 3.79 0.63 0 0.63 0.65 0.25 0.9
Beta-lactam and penicilins 174.39 3.9 174.39 52.21 21.48 73.69 54.4 11.1 65.5
Other beta-lactam 895.3 0.48 895.78 221.8 12.42 234.22 249.89 12.38 262.27
Aminoglycozide 192.83 0 192.83 132.1 132.1 76.23 0 76.23
Macrolides and lincosamides 14.24 4.49 18.73 38.86 1.65 40.51 33.07 1 34.07
Quinolone 161.9 13.1 175 11.6 33.6 45.2 37.4 35.6 73
Other antibacterials 209.28 21.87 231.15 36.8 2.87 39.67 34.82 3.5 38.32
Antimycotics 49.71 46 95.71 0.11 15.6 0.11 1.31 17.2 18.51
Total 1701 95.81 1796.81 494.1 72.02 566.12 487.77 96.28 584.05
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hospitals from worldwide countries represents an important 
argument, which encourages to improve the quality of the 
treatment, planning, rational prescription and utilisation of 
antibiotics in hospitals.  
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